Non-mydriatic retinal camera Aurora® AEYE

hand-held

On-the-spot detection of diabetic retinopathy with the handheld AI fundus camera Redefine Diabetic Retinopathy Detection with Optomed Aurora AEYE: The First FDA-Cleared Handheld AI Fundus Camera Only one image per eye without dilation Results in less than 60 seconds No startup costs and fixed monthly fee Revolutionizing Diabetic Eye Screening with Optomed Aurora AEYE With unparalleled portability and adaptability, our solution sets a new standard in diabetic retinopathy screening that can be performed by any trained healthcare professional during routine patient exams. FDA-cleared and clinically validated, it delivers desktop image quality2 in a handheld device, enabling screenings anywhere and anytime. Our solution is here to close the care-gap and drive significant improvements in patient outcomes and healthcare ratings. Pioneering a New Era with Autonomous AI Technology As the first FDA-cleared handheld AI fundus camera, our solution is clinally validated delivering accuracy with over 90% sensitivity and specificity3. The Optomed Aurora AEYE stands alone in its ability to detect more than mild diabetic retinopathy with unmatched accuracy and precision. Our solution sets a new standard for autonomous AI-powered diabetic retinopathy detection that can be performed by any trained healthcare professional, anywhere. The Optomed Aurora AEYE advances healthcare, improves patient outcomes, and provides greater accessibility to all. This new FDA clearance is based on two large-scale prospective phase-III studies, in which AEYE-DS demonstrated best-in-class efficacy and imageability.